As of Friday close, AstraZeneca PLC’s (NASDAQ:AZN) stock was up $0.81, moving up 1.21 percent to $67.83. The average number of shares traded per day over the past five days has been 4,757,220 shares. 3 times new highs have been achieved over the past 5 days, with a -$0.44 fall in that time frame. In the last twenty days, the average volume was 4,130,480, while in the previous 50 days, it was 4,835,198.
Since last month, AZN stock retreated -1.84%. Shares of the company fell to $65.71 on 09/11/23, the lowest level in the past month. A 52-week high of $76.56 was reached on 04/25/23 after having rallying from a 52-week low of $52.65. Since the beginning of this year, AZN’s stock price has risen by 0.04% or $0.03, and marked a new high 12 times. However, the stock has declined by -11.40% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Right now, AstraZeneca PLC (AZN) has a P/E ratio of about 34.34. The stock’s beta is 0.51. Besides these, the trailing price-to-sales (P/S) ratio of 4.67, the price-to-book (PB) ratio of 5.62, and the price-to-cash flow ratio of 31.70 may also be considered.
The latest dividend of $0.4650 per share was paid out, which is -52.79% less than last year’s $0.9850. On Friday July 28 2023, a $0.52 dividend decrease was announced.
Financial Health
In the three months ended June 29, AstraZeneca PLC’s quick ratio stood at 0.70, while its current ratio was 0.90, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.67, and the total debt-to-equity ratio was 0.80. On the profitability front, the trailing twelve-month gross margin is 80.80% percent. In the year ended June 29, EBITDA margin amounted to 23.26%, whereas operating margins totaled 16.50%. Based on annual data, AZN earned $31.96 billion in gross profit and brought in $44.35 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 6.90%. Return on equity (ROE) for the past 12 months was 17.00%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. AZN’s revenue rose 15.63% during the quarter, while net income inched up to $44.35 billion. While analysts expected AstraZeneca PLC to report $0.95 quarterly earnings, the actual figure was $1.08 per share, beating the consensus estimate by 13.70%. During the quarter, the company generated $3.73 billion in EBITDA. The liabilities of AstraZeneca PLC were 59.13 billion at the end of its most recent quarter ended June 29, and its total debt was $30.79 billion.
Technical Picture
This quick technical analysis looks at AstraZeneca PLC’s (AZN) price momentum. With a historical volatility rate of 23.63%, the RSI 9-day stood at 51.24% on 22 September.
With respect to its five-day moving average, the current AstraZeneca PLC price is down by -0.64% percent or -$0.44. At present, AZN shares trade -0.09% below its 20-day simple moving average and -7.71% percent below its 100-day simple moving average. However, the stock is currently trading approximately +0.18% above its SMA50 and -0.86% below its SMA200.
Stochastic coefficient K was 58.64% and Stochastic coefficient D was 47.45%, while ATR was 1.25. Given the Stochastic reading of 66.41% for the 14-day period, the RSI (14) reading has been calculated as 49.23%. As of today, the MACD Oscillator reading stands at 0.28, while the 14-day reading stands at 0.22.
Analyst Ratings
HSBC Securities launched its rating on AstraZeneca PLC (NASDAQ: AZN) to a Buy in a note to investors on July 14, 2023. AstraZeneca PLC (AZN) has been rated Buy by analysts. According to 0 brokerage firms, AZN is a sell, and 5 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate AstraZeneca PLC stock as buy, with 24 recommending it as overweight.
With a median target price of $82.97, the current consensus forecast for the stock is $63.00 – $106.75. Based on these forecasts, analysts predict AstraZeneca PLC (AZN) will achieve an average price target of $83.43.
